Acumen Pharmaceuticals announced positive Phase 1 clinical trial results for sabirnetug (ACU193), a potential Alzheimer’s diseaseAlzheimer’s disease treatment targeting amyloid beta oligomers (AβOs). Published in the •Journal of Prevention of Alzheimer’s Disease•, the INTERCEPT-AD trial data showed sabirnetug was well-tolerated, effectively engaged AβOs, and reduced amyloid plaques in higher dose groups. A Phase 2 trial, ALTITUDE-AD, is underway with anticipated enrollment completion in the first half of 2025.
This news is noteworthy because it validates the targeting of AβOs as a potential therapeutic strategy for Alzheimer’s disease. While amyloid plaques have been a traditional focus of Alzheimer’s research, increasing evidence suggests that soluble AβOs play a critical role in the disease’s progression. Sabirnetug’s demonstrated ability to selectively target these oligomers differentiates it from existing therapies and offers a promising new avenue for treatment. The positive safety profile observed in the Phase 1 trial further strengthens the rationale for continued development.
The INTERCEPT-AD trial enrolled 65 participants with early-stage Alzheimer’s disease. Results demonstrated dose-dependent target engagement of AβOs and statistically significant amyloid plaque reduction at higher doses. The incidence of amyloid-related imaging abnormalities (ARIA), a potential side effect associated with some Alzheimer’s therapies, was low, with one case of mild, resolved ARIA-E. Notably, none of the participants with a high-risk genetic profile (apolipoprotein E Ɛ4 homozygotes) who received sabirnetug developed ARIA.
The positive Phase 1 data reinforces the potential of sabirnetug as a next-generation Alzheimer’s treatment. The ongoing Phase 2 ALTITUDE-AD trial will be crucial in further evaluating the efficacy of sabirnetug in a larger patient population and determining its potential to slow cognitive and functional decline. Positive results from this trial could significantly impact the Alzheimer’s treatment landscape and offer new hope for patients.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
